PIPELINE AND CLINICAL PROGRAMS

A POWERFUL RESEARCH AND DEVELOPMENT ENGINE

Our pipeline is powered by end-to-end research and development capabilities. The Research team discovers promising new drug compounds. From there, Global Development brings these investigational candidates through the full clinical development process, from trial design to study execution and lifecycle management. Our product portfolio reflects the true collaborative spirit of Regeneron.

Explore the Regeneron clinical pipeline

Select therapeutic area(s):
Select phase(s):
Select collaborator(s):

Displaying item

Clear Filters

Phase 1

  • REGN6569
    GITR Antibody Solid tumors
  • ODRONEXTAMAB
    CD20 X CD3 Antibody B-cell malignancies
  • REGN4018
    MUC16 X CD3 Antibody Platinum-resistant ovarian cancer
  • REGN5459
    BCMA X CD3 Antibody Multiple myeloma
  • REGN5678
    PSMA X CD28 Antibody Prostate cancer
  • REGN5093
    MET X MET Antibody MET-altered advanced non-small cell lung cancer (NSCLC)
  • REGN7257
    IL-2Rg Antibody Aplastic anemia
  • CASIRIVIMAB WITH IMDEVIMAB
    SARS-CoV-2 Virus Multi-Antibody Therapy Multi-dose safety study in healthy volunteers
  • REGN5381
    NPR1 Agonist Antibody Heart failure
  • FIANLIMAB
    LAG-3 Antibody Solid tumors, advanced hematologic malignancies
  • REGN5668
    MUC16 x CD28 Ovarian cancer
  • REGN7075
    EGFR x CD28 Solid tumors
  • REGN6490
    IL-36R Antibody Palmo-plantar pustulosis
  • ALN-HSD5
    HSD17B13 RNAi Therapeutic Nonalcoholic steatohepatitis
  • POZELIMAB + CEMDISIRAN5
    C5 Antibody + C5 siRNA Therapeutic Paroxysmal nocturnal hemoglobinuria
  • NTLA-20014
    CRISPR/Cas9 Hereditary transthyretin amyloidosis with polyneuropathy

Phase 2

  • AFLIBERCEPT3
    VEGF-Trap High-dose (8 mg) for wet age-related macular degeneration (AMD)
  • CEMIPLIMAB1
    PD-1 Antibody Basal cell carcinoma (BCC), metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), neoadjuvant CSCC
  • ODRONEXTAMAB
    CD20 X CD3 Antibody B-cell non-Hodgkin lymphoma
  • REGN5458
    BCMA X CD3 Antibody Multiple myeloma
  • SARILUMAB1
    IL-6R Antibody Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis
  • DUPILUMAB1
    IL-4R Antibody Peanut allergy, grass allergy
  • REGN1908-1909
    Fel d 1 Multi-Antibody Therapy Cat allergy
  • EVINACUMAB
    ANGPTL-3 Antibody Severe hypertriglyceridemia
  • REGN4461
    LEPR Agonist Antibody Generalized lipodystrophy
  • GARETOSMAB
    Activin-A Antibody Fibrodysplasia ossificans progressiva (FOP)
  • POZELIMAB
    C5 Antibody CD-55 deficient protein-losing enteropathy
  • CEMDISIRAN5
    C5 siRNA Therapeutic Immunoglobulin A nephropathy
  • CASIRIVIMAB WITH IMDEVIMAB
    SARS-CoV-2 Virus Multi-Antibody Therapy Dose-ranging virology study in non-hospitalized patients

Phase 3

  • AFLIBERCEPT3
    VEGF-Trap Retinopathy of prematurity (ROP), high-dose formulation (8 mg) for wet age-related macular degeneration (AMD) and diabetic macular edema (DME)
  • CEMIPLIMAB1
    PD-1 Antibody Non-small cell lung cancer (NSCLC) chemo combination, cervical cancer, adjuvant cutaneous squamous cell carcinoma (CSCC)
  • DUPILUMAB1
    IL-4R Antibody Atopic dermatitis in pediatric patients 6 mo.–5 y.o, hand and foot atopic dermatitis, asthma in pediatric patients 6-11 y.o., eosinophilic esophagitis in patients 6 and older, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, prurigo nodularis, chronic spontaneous urticaria, allergic bronchopulmonary aspergillosis, chronic inducible urticaria, chronic sinusitis without nasal polyposis, allergic fungal rhinosinusitis
  • CASIRIVIMAB WITH IMDEVIMAB
    SARS-CoV-2 Virus Multi-Antibody Therapy Treatment for certain hospitalized and non-hospitalized patients with COVID-19; prevention of COVID-19 in household contacts of diagnosed patients
  • ALIROCUMAB
    PCSK9 Antibody Heterozygous familial hypercholesterolemia (HeFH) in pediatrics
  • FASINUMAB2
    NGF Antibody Osteoarthritis pain of the knee or hip
  • ITEPEKIMAB1
    IL-33 Antibody Chronic obstructive pulmonary disease (COPD)
  • REGN5713-5714-5715
    Bet v 1 Multi-Antibody Therapy Birch allergy

No results found. Please adjust your filter selection and try again.

1Sanofi

2Teva and Mitsubishi Tanabe

3Bayer

4Intellia

5Alnylam

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

Regeneron's therapeutic research areas

Scientific trailblazers

Following the science leads to unexpected breakthroughs and diverse areas of study —from ophthalmology to cancer to inflammation to pain to cardiovascular disease.

Our Current Research

Putting antibodies in action

Putting antibodies in action

Our scientists are leading the way, developing new technologies to help discover better and novel antibodies. Discover the past, present and future of antibody medicine.

More About Antibody Medicine

Back to top